These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24809052)
1. Kallikreins as biomarkers for prostate cancer. Hong SK Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052 [TBL] [Abstract][Full Text] [Related]
2. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Ulmert D; Vickers AJ; Scher HI; Becker C; Iversen P; Frankel D; Jensen JK; Olesen TK; Lilja H Clin Chem Lab Med; 2012 Nov; 50(11):1993-8. PubMed ID: 22718641 [TBL] [Abstract][Full Text] [Related]
3. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thorek DL; Evans MJ; Carlsson SV; Ulmert D; Lilja H Thromb Haemost; 2013 Sep; 110(3):484-92. PubMed ID: 23903407 [TBL] [Abstract][Full Text] [Related]
5. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781 [TBL] [Abstract][Full Text] [Related]
6. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557 [TBL] [Abstract][Full Text] [Related]
7. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196 [TBL] [Abstract][Full Text] [Related]
8. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522 [TBL] [Abstract][Full Text] [Related]
9. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300 [TBL] [Abstract][Full Text] [Related]
10. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195 [TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905 [TBL] [Abstract][Full Text] [Related]
13. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177 [TBL] [Abstract][Full Text] [Related]
14. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124 [TBL] [Abstract][Full Text] [Related]
15. PSA and other tissue kallikreins for prostate cancer detection. Stephan C; Jung K; Lein M; Diamandis EP Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069 [TBL] [Abstract][Full Text] [Related]
16. Predictions for the future of kallikrein-related peptidases in molecular diagnostics. Scorilas A; Mavridis K Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162 [TBL] [Abstract][Full Text] [Related]
17. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
18. Emerging biomarkers in the detection and prognosis of prostate cancer. Filella X; Foj L Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761 [TBL] [Abstract][Full Text] [Related]
19. Activation and activity of glycosylated KLKs 3, 4 and 11. Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661 [TBL] [Abstract][Full Text] [Related]
20. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]. Lein M; Stephan C; Jung K; Schnorr D; Loening SA Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]